Janssen Sues Teva for Infringing Invega Sustanna Patents

Drug Industry Daily
A A
Janssen filed suit in a federal court against Teva last week alleging patent infringement of its schizophrenia drug Invega Sustanna — a product that brought in more than $2 billion in 2016.

To View This Article:

Login

Subscribe To Drug Industry Daily